Features

What are the pressing issues shaping the market for fine chemicals and pharma ingredients in 2026—the challenges and the opportunities? Senior executives from CDMOs share their perspectives.  

The European Parliament has endorsed its position on the Critical Medicines Act, setting the stage to finalize the law to assure security of supply for essential medicines in the EU.

What can CDMOs/CMOs expect in 2026? DCAT Value Chain Insights looks at the issues shaping the market for bio/pharmaceutical outsourcing in the coming year: key trends, fundamentals, and the variables influencing the sector’s performance.

Evolving US tariff policy is a key variable in the cost structures, manufacturing strategies, and supply chains of bio/pharma companies and their suppliers. A DCAT webinar gives an executive briefing…

What are the key issues on the bio/pharmaceutical industry’s radar in 2026? DCAT Value Chain Insights weighs in on the key trends and developments shaping the industry in the year ahead: from manufacturing and supply lines to product innovation and new drug development.

Does your company have major company news that it would like to share at DCAT Week? DCAT Member Companies are invited to apply to present at the Member Company Announcement Forum, a valuable platform in which senior executives make significant news announcements.

As 2025 comes to a close, what were the key developments—expansions and M&A—from CDMOs/CMOs this year? DCAT Value Chain Insights looks at the companies and moves that topped the headlines this year.

The European Commission, the European Parliament, and the Council of the European Union, have agreed to a proposal for the EU’s landmark pharma legislation, setting the stage for major reforms.

Without question, US-imposed tariffs and ensuing trade deals and the impact on the bio/pharma industry was the number one news story in 2025, going hand-in-hand with US manufacturing investments and drug pricing reforms. What else made the news?

The UK and the US governments have agreed in principle on drug pricing and tariffs/trade on pharmaceuticals between the two countries, months after the countries formed an initial trade pact. What is the new deal and the impact on pharma?